Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826).
Nivolumab-based immunotherapy works better than standard chemotherapy for advanced Hodgkin lymphoma in all patient groups, including those historically hardest to treat.
In a prespecified subset analysis of the Phase III SWOG S1826 trial, nivolumab-AVD demonstrated superior PFS over BV-AVD in advanced Hodgkin lymphoma across all EBV and histologic subgroups, with the greatest benefit in EBV-positive and non-nodular sclerosis patients—historically the poorest-prognosis groups. These results directly support N-AVD as frontline standard of care for all advanced cHL regardless of biologic subgroup.
What the study was
- Study design
- Prespecified subset analysis of Phase III RCT (SWOG S1826, NCT03907488)
- Population
- Stage III-IV classic Hodgkin lymphoma (n=970 eligible; EBV n=522, histology n=664)
- Sample size
- 970
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Blood Advances
Why it surfaced
Phase III prespecified subset analysis showing N-AVD overcomes historically poor prognosis of EBV+ and non-NS Hodgkin lymphoma; defines frontline standard of care for all advanced cHL subgroups.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.